Skip to content

SEARCH icon
  • Investing
  • Tech
    • Application Software
    • Communications
    • Computer Hardware
    • Online Media
    • Semiconductors
  • Consumer
    • Autos
    • Beverages
    • Consumer Packaged Goods
    • Entertainment
    • Manufacturing
    • Restaurants
    • Retail
    • Travel & Leisure
  • Financial
    • Asset Management
    • Banks
    • Brokers & Exchanges
    • Credit Services
    • Insurance
  • Politics
    • Trump
    • US Budget
  • Health
    • Healthcare
    • Biotechnology
    • Drug Manufacturers
    • Pharmaceutical
  • Basic Materials
    • Agriculture
    • Metals & Mining
      • Cobalt
      • Zinc
      • Gold
      • Silver
      • Lithium
      • Uranium
      • Copper
  • Energy
    • Oil & Gas
    • Alternative Energy
      • Biofuels
      • Hydro
      • Solar
  • Industrials
    • Aerospace and Defense
    • Airlines
    • Business Services
    • Consulting and Outsourcing
    • Farm & Construction Machinery
    • Industrial Products
    • Transportation & Logistics
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Tech
    • Application Software
    • Communications
    • Computer Hardware
    • Online Media
    • Semiconductors
  • Consumer
    • Autos
    • Beverages
    • Consumer Packaged Goods
    • Entertainment
    • Manufacturing
    • Restaurants
    • Retail
    • Travel & Leisure
  • Financial
    • Asset Management
    • Banks
    • Brokers & Exchanges
    • Credit Services
    • Insurance
  • Politics
    • Trump
    • US Budget
  • Health
    • Healthcare
    • Biotechnology
    • Drug Manufacturers
    • Pharmaceutical
  • Basic Materials
    • Agriculture
    • Metals & Mining
      • Cobalt
      • Zinc
      • Gold
      • Silver
      • Lithium
      • Uranium
      • Copper
  • Energy
    • Oil & Gas
    • Alternative Energy
      • Biofuels
      • Hydro
      • Solar
  • Industrials
    • Aerospace and Defense
    • Airlines
    • Business Services
    • Consulting and Outsourcing
    • Farm & Construction Machinery
    • Industrial Products
    • Transportation & Logistics

icon

      Homeinvest in biotech

      invest in biotech

      BIO-TECHNE RELEASES MITOBRILLIANT(TM) FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS
      Biotechnology

      BIO-TECHNE RELEASES MITOBRILLIANT(TM) FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS

      December 5, 2022
      Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm
      Biotechnology

      Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm

      December 4, 2022
      Ultragenyx (RARE) Down 0.9% Since Last Earnings Report: Can It Rebound?
      Biotechnology

      Ultragenyx (RARE) Down 0.9% Since Last Earnings Report: Can It Rebound?

      December 2, 2022
      Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?
      Biotechnology

      Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?

      December 2, 2022
      Why Is Horizon Therapeutics (HZNP) Up 38.3% Since Last Earnings Report?
      Health

      Why Is Horizon Therapeutics (HZNP) Up 38.3% Since Last Earnings Report?

      December 2, 2022
      Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound?
      Biotechnology

      Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound?

      December 2, 2022
      Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?
      Health

      Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?

      December 2, 2022
      Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?
      Health

      Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?

      December 2, 2022
      Halozyme- “Easy to Love”
      Biotechnology

      Halozyme- “Easy to Love”

      December 2, 2022
      Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
      Biotechnology

      Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

      December 1, 2022
      « 1 … 9 10 11 12 13 … 540 »

       

      LATEST NEWS

      • Investing News Big Banks Set to Release Earnings
      • Investing News JPMorgan Chase Stock Analysis
      • Investing News Goldman Sachs Earnings Preview
      • Investing News Top Vanguard ETFs to Hold Forever
      • Investing News Earnings Reports to Watch This Week

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from StreetSignals.

      I want e-mail alerts, updates, and offers and agree to the StreetSignals privacy policy.

      Market Jar Media Inc. © 2025